Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$338 Mln
P/E Ratio
--
P/B Ratio
2.05
Industry P/E
--
Debt to Equity
0.01
ROE
-1.01 %
ROCE
-99.85 %
Div. Yield
0 %
Book Value
2.42
EPS
-4.44
CFO
$-290.14 Mln
EBITDA
$-295.70 Mln
Net Profit
$-296.64 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Amylyx Pharmaceuticals (AMLX)
| 5.29 | 9.79 | 13.71 | 98.01 | -30.41 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Amylyx Pharmaceuticals (AMLX)
| -74.03 | -60.16 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes... avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 43 Thorndike Street, Cambridge, MA, United States, 02141 Read more
Co-Founder, Co-CEO & Director
Mr. Joshua B. Cohen
Co-Founder, Co-CEO & Director
Mr. Joshua B. Cohen
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Amylyx Pharmaceuticals Inc (AMLX) stood at $ 194 Mln as on 31-Dec-24
The share price of Amylyx Pharmaceuticals Inc (AMLX) is $3.98 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Amylyx Pharmaceuticals Inc (AMLX) has given a return of -30.41% in the last 3 years.
Amylyx Pharmaceuticals Inc (AMLX) has a market capitalisation of $ 338 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Amylyx Pharmaceuticals Inc (AMLX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Amylyx Pharmaceuticals Inc (AMLX) and enter the required number of quantities and click on buy to purchase the shares of Amylyx Pharmaceuticals Inc (AMLX).
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 43 Thorndike Street, Cambridge, MA, United States, 02141
The CEO & director of Mr. Joshua B. Cohen. is Amylyx Pharmaceuticals Inc (AMLX), and CFO & Sr. VP is Mr. Joshua B. Cohen.
There is no promoter pledging in Amylyx Pharmaceuticals Inc (AMLX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Amylyx Pharmaceuticals Inc. (AMLX) | Ratios |
|---|---|
|
Return on equity(%)
|
-100.88
|
|
Operating margin(%)
|
-334.07
|
|
Net Margin(%)
|
-345.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Amylyx Pharmaceuticals Inc (AMLX) was $0 Mln.
$0.16
(
